Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses

David A Muller, Frances E Pearson, Germain J P Fernando, Christiana Agyei-Yeboah, Nick S Owens, Simon Robert Corrie, Michael L Crichton, Jonathan C J Wei, William Clyde Weldon, M Steven Oberste, Paul R Young, Mark Anthony Fernance Kendall

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)


Polio eradication is progressing rapidly, and the live attenuated Sabin strains in the oral poliovirus vaccine (OPV) are being removed sequentially, starting with type 2 in April 2016. For risk mitigation, countries are introducing inactivated poliovirus vaccine (IPV) into routine vaccination programs. After April 2016, monovalent type 2 OPV will be available for type 2 outbreak control. Because the current IPV is not suitable for house-to-house vaccination campaigns (the intramuscular injections require health professionals), we developed a high-density microprojection array, the Nanopatch, delivered monovalent type 2 IPV (IPV2) vaccine to the skin. To assess the immunogenicity of the Nanopatch, we performed a dose-matched study in rats, comparing the immunogenicity of IPV2 delivered by intramuscular injection or Nanopatch immunisation. A single dose of 0.2 D-antigen units of IPV2 elicited protective levels of poliovirus antibodies in 100% of animals. However, animals receiving IPV2 by IM required at least 3 immunisations to reach the same neutralising antibody titres. This level of dose reduction (1/40th of a full dose) is unprecedented for poliovirus vaccine delivery. The ease of administration coupled with the dose reduction observed in this study points to the Nanopatch as a potential tool for facilitating inexpensive IPV for mass vaccination campaigns.
Original languageEnglish
Article number22094
Pages (from-to)1 - 7
Number of pages7
JournalScientific Reports
Publication statusPublished - 25 Feb 2016
Externally publishedYes

Cite this